Lanvis (Tioguanine)

Tioguanine is converted inside cells to thioguanine nucleotides, which become incorporated into DNA and RNA. This incorporation disrupts normal purine synthesis, leading to faulty DNA replication and transcription, ultimately causing cytotoxicity of rapidly dividing malignant cells and providing immunosuppressive effects.

The dose of Lanvis is individualized and must be determined by the prescribing oncologist or hematologist. Dosage depends on factors such as the specific leukemia being treated, patient age, weight, renal and hepatic function, and concurrent therapies.

Safety of tioguanine in pregnancy or lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs the possible risk to the fetus or infant, and this decision must be made by a qualified specialist after thorough risk assessment.

To order Lanvis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

Lanvis (tioguanine) is one of several thiopurine agents, including azathioprine and mercaptopurine. While all share a similar mechanism of interfering with purine synthesis, tioguanine is often selected for specific leukemic protocols because of its pharmacokinetic profile and potency. Choice of agent depends on disease type, treatment regimen, and individual patient tolerance.

Lanvis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and out of reach of children. Do not refrigerate or freeze unless the manufacturer’s labeling specifically indicates otherwise.

Lanvis is administered orally, typically as tablets or capsules, and should be taken with water as directed by the prescribing clinician. The exact timing (e.g., with or without food) and frequency are determined by the treating physician based on the therapeutic plan.

The most serious risks include severe myelosuppression, which can lead to life‑threatening infections, hepatotoxicity, pancreatitis, and rare hypersensitivity reactions. Patients should be closely monitored with regular blood counts and liver function tests, and any signs of infection or organ dysfunction should prompt immediate medical evaluation.

Lanvis should be avoided in individuals with known hypersensitivity to tioguanine or other thiopurines, in patients with severe active infections, and in those with significant hepatic or renal impairment unless dose adjustments are made. Pregnant or breastfeeding women should only use it when clearly indicated by a specialist.